446 related articles for article (PubMed ID: 16176562)
1. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
2. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
Kudo T; Hisaka A; Sugiyama Y; Ito K
Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
[TBL] [Abstract][Full Text] [Related]
6. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
[TBL] [Abstract][Full Text] [Related]
7. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
Varma MV; Lai Y; Kimoto E; Goosen TC; El-Kattan AF; Kumar V
Pharm Res; 2013 Apr; 30(4):1188-99. PubMed ID: 23307347
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance.
Säll C; Houston JB; Galetin A
Drug Metab Dispos; 2012 Jul; 40(7):1279-89. PubMed ID: 22451699
[TBL] [Abstract][Full Text] [Related]
10. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
Diabetologia; 2003 Mar; 46(3):347-51. PubMed ID: 12687332
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions.
Kudo T; Goda H; Yokosuka Y; Tanaka R; Komatsu S; Ito K
J Pharm Sci; 2017 Sep; 106(9):2847-2852. PubMed ID: 28238899
[TBL] [Abstract][Full Text] [Related]
12. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide.
Bidstrup TB; Stilling N; Damkier P; Scharling B; Thomsen MS; Brøsen K
Eur J Clin Pharmacol; 2004 Apr; 60(2):109-14. PubMed ID: 15034704
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
14. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
[TBL] [Abstract][Full Text] [Related]
15. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
Wang JS; DeVane CL
Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
[TBL] [Abstract][Full Text] [Related]
16. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.
Tornio A; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Aug; 62(8):645-51. PubMed ID: 16832679
[TBL] [Abstract][Full Text] [Related]
17. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
[TBL] [Abstract][Full Text] [Related]
18. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
Wang JS; Neuvonen M; Wen X; Backman JT; Neuvonen PJ
Drug Metab Dispos; 2002 Dec; 30(12):1352-6. PubMed ID: 12433802
[TBL] [Abstract][Full Text] [Related]
19. Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
Doki K; Darwich AS; Achour B; Tornio A; Backman JT; Rostami-Hodjegan A
Br J Clin Pharmacol; 2018 May; 84(5):972-986. PubMed ID: 29381228
[TBL] [Abstract][Full Text] [Related]
20. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Tornio A; Niemi M; Neuvonen M; Laitila J; Kalliokoski A; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2008 Sep; 84(3):403-11. PubMed ID: 18388877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
